Sandoz sees itself on track after first half-year

At Group level, the former Novartis subsidiary generated sales of USD 5.2 billion in the first six months. This was an increase of 4 percent compared to the previous year - both in the reporting currency, the US dollar, and at constant exchange rates. Sandoz is therefore well on the way to achieving its own target: for the year as a whole, sales are expected to grow by a mid-single-digit percentage.

Of the two divisions, the Generics business contributed 3.7 billion dollars to total sales and thus grew by 1 percent at constant exchange rates. Revenue increased slightly in all regions.

The smaller biosimilar division achieved sales of 1.5 billion (+12%). While the European business benefited from the more recent launches, the biosimilar Omnitrope (somatropin) made a significant contribution to the good performance in the international business. However, the most important biosimilar launches in the international business are more likely to take place in the second half of the year, Sandoz confirms earlier announcements.

At the profit level, Sandoz reported core operating profit (core EBITDA) of USD 1.05 billion (+20%). The corresponding margin amounted to 20 percent after 17.5 percent in the same period of the previous year. The bottom line was USD 635 million, 30% more than in the first half of 2024.

The Basel-based company confirms its previous target for the further course of business: net sales are expected to continue to grow in the mid-single-digit range and the core EBITDA margin is expected to remain at around 21% in 2025.